Skip to main content

Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
hydroxyurea
Description

In this analysis, we characterized use of hydroxyurea among patients with sickle cell disease (SCD) in the Sentinel Distributed Database (SDD). This analysis contains two reports:

  • Report 1: We described use of hydroxyurea among patients with SCD in the SDD. The study period includes data from January 1, 2000 to December 31, 2020. We distributed this request to seven Sentinel Data Partners on July 27, 2021.
  • Report 2: We described patients with SCD who were and were not dispensed hydroxyurea, and estimated the number of hospitalizations and emergency department visits among those patients in the SDD. The study period includes data from January 1, 2000 to September 30, 2020. We distributed this request to seven Sentinel Data Partners on April 30, 2021.
Deliverables (2)
Sentinel Modular Program Report: Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis, Report 1 Sentinel Modular Program Report: Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2000 - December 31, 2020; January 1, 2000 - September 30, 2020
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)